CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02588651
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:56.617170+00:00
Published At: 2025-11-21T00:00:00+00:00
Record Updated At: 2025-11-21
Results Posted At: 2025-11-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["T-cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Hepato-splenic T-cell Lymphoma", "Adult T-cell Leukemia/Lymphoma", "Enteropathy Associated T-cell Lymphoma", "NK T-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-21"
protocolSection.identificationModule.nctId: "NCT02588651"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (\u003c10%) Mature T Cell Lymphoma (TCL)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-11-21"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.